www.innocyto.com

InnoCyto Inc.

15375 Barranca Pkwy, Suite I-103
Irvine, CA 92618
Email: info@innocyto.com
Phone: 1-949-418-7543

iF647 Anti-human CD269 (BCMA) Antibody

Catalog Number:	114001, 114002
Size:	25 tests, 100 tests
Target Name:	BCMA, BCM, TNFRSF17, CD269
Regulatory Status:	RUO

PRODUCT DETAILS

Clone:	Belantamab
Application:	Flow Cytometry
Reactivity:	Human
Format:	iF647
Isotype:	Human IgG1
Antibody Type:	Monoclonal
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA
Protein Concentration:	Supplied at a lot-specific concentration.
Storage&Handling:	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Recommended Usage:	For flow cytometric staining, it is recommended to use 5 uL of this reagent per 0.5-1.0 million cells in a 100 µL volume. Optimal reagent performance should be determined by titration for each specific application.
Excitation Laser:	Red Laser (633 nm)
Isotype Control:	301207

BACKGROUND INFORMATION

Human B-cell maturation antigen (BCMA), also known as CD269 or TNFRSF17, is a cell-surface receptor belonging to the tumor necrosis factor receptor (TNFR) superfamily. Encoded by the TNFRSF17 gene, BCMA is expressed predominantly on mature B cells, plasmablasts, and plasma cells. It plays a crucial role in B-cell maturation, plasma-cell survival, and antibody production by supporting the maintenance of antibody-secreting cells. BCMA signaling contributes to humoral immunity and helps sustain long-lived plasma cells responsible for producing protective antibodies.


BCMA is a type III transmembrane protein characterized by an extracellular domain containing cysteine-rich motifs, a single transmembrane segment, and an intracellular domain involved in signal transduction. Its two principal ligands are B-cell activating factor (BAFF, also known as BLyS) and a proliferation-inducing ligand (APRIL). APRIL generally binds BCMA with high affinity, while BAFF can also interact with BAFF-R and TACI, two other receptors in the TNF receptor family. Ligand binding promotes signaling pathways, including NF-κB activation, that support plasma-cell survival, proliferation, and immunoglobulin production. BCMA can also undergo proteolytic shedding, generating soluble BCMA that may serve as a biomarker of plasma-cell activity and disease

burden.

BCMA is particularly important in multiple myeloma, a malignancy of antibody-producing plasma cells. Malignant plasma cells commonly express BCMA, and its signaling can support their survival and persistence within the bone marrow microenvironment. Elevated soluble BCMA levels may correlate with disease burden and treatment response. Because BCMA expression is concentrated on the plasma-cell lineage, it provides a useful target for selectively directing therapies toward malignant plasma cells.

BCMA has become a major target in multiple myeloma treatment. Therapeutic approaches include BCMA-directed chimeric antigen receptor (CAR) T-cell therapies, bispecific antibodies that connect BCMA-expressing cells to T cells, and antibody-drug conjugates that deliver cytotoxic agents to malignant plasma cells. These strategies have demonstrated clinical benefit in multiple myeloma, although treatment resistance and adverse effects remain important considerations. Human BCMA is widely used in immunology research, plasma-cell biology, biomarker development, and targeted cancer immunotherapy.

PRODUCT DATA



Fc-tagged fusion BCMA protein-coated beads (70%) mixed with non-coated beads (30%) were stained with i F647 Anti-Human BCMA clone Belantamab (color-filled histogram) or an isotype control (gray histogram).

This product is supplied subject to the terms and conditions at www.innocyto.com/web/terms.php and may only be used as provided in the stated terms. Products are for Research Use Only.